Recruiting

Resistance Exercise with GLP-1 RAs

Sponsor:

University of Pittsburgh

Code:

NCT07652333

Conditions

Muscle Composition

Obesity

Quality of Life (QOL)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Resistance Exercise

GLP-1 RAs

Study Details

Brief summary:

The purpose of this study is to examine the effects of resistance exercise, such as weightlifting, on retention of muscle mass and mental health in individuals taking GLP-1 RAs (an obesity medication). Resistance exercise is focused on increasing the strength of participants' muscles, such as how much participant can lift.

•The duration of this study is 3 months. This includes:

  • Orientation session to explain study protocol, exercise program, and complete questionnaire about participants' medical history and lifestyle.
  • Two health assessments at baseline and at 3 months. These assessments include body composition, resting blood pressure, cardiovascular function, and muscular strength. Both the resistance exercise group and the control group will complete assessments at baseline and again at 3 months. After the 3-month period, individuals in the control group may choose to participate in the exercise training and complete the optional 6-month assessments.
  • Personalized resistance exercise sessions for 60 minutes per session, twice per week, for 3 months.

Conditions

Muscle Composition

Obesity

Quality of Life (QOL)

Study ID

NCT07652333

Start date

May 25, 2026

Status verified date

Jun, 2026

Completion date

May 31, 2027

Anticipated

Primary completion date

Apr 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Initiating GLP-1 RAs prescribed by physician or advanced practice practitioner and willing to withhold the start of the drug until baseline assessment completed
  • Non-Smoker
  • ≥18 years old
  • Obese: Body Mass Index 30-45 kg/m² or BMI ≥27 + ≥1 weight related comorbidity; either hypertension or sleep apnea confirmed by participant self-report
  • Inactive: not meeting the current US exercise guidelines over the past 6 months
  • Capable of performing the required exercise training

Exclusion Criteria:

  • A serious heart condition, such as unstable heart disease or heart failure, irregular heartbeats that are not well controlled, severe narrowing of the heart valves, or any recent inflammation of the heart or its lining
  • Cancer requiring treatment in the past 5 years
  • Hypothyroidism/hyperthyroidism
  • Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome type 2 (MEN2)
  • Gastroparesis
  • Chronic/idiopathic acute pancreatitis
  • Hepatic disease or cirrhosis
  • Struggle with alcohol or other substance abuse (heavy drinking (≥4 drinks/day or ≥8 drinks/week for women; ≥5 drinks/day or ≥15 drinks/week for men), or who score ≥3 on the Drug Abuse Screening Test (DAST-10))
  • Diabetes (Type 1 or 2)
  • Major risk factors for coronary heart disease such as uncontrolled high blood pressure (≥160 mm Hg systolic or ≥100 mm Hg diastolic)
  • Problems with your muscles or bones that limit your ability to exercise
  • Any other medical condition that is life-threatening, can interfere with or be aggravated by the exercise training
  • Plans to be away ≥2 weeks in the next 3 months
  • Participation in any other concurrent interventional clinical trial
  • History of eating disorders or weight-loss surgery, unstable weight (±5% change in past 6 months), or use of obesity medication (e.g., such as Wegovy, Ozempic, Saxenda, Zepbound, Mounjaro) in the last 3 months
  • Inability to give informed consent
  • History of major depression or other severe psychiatric disorders (e.g., who answer "yes" to question 9 on PHQ-9 in the Psych\_QoL\_Sleep questionnaires.)
  • Pregnant or plan to become pregnant during study

Study Design

Enrollment

40 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Resistance Exercise (RE)

Participants will perform 60 min of resistance exercise 2 sessions per week for 12 weeks while continuing GLP-1 RAs therapy as prescribed by regular treating provider

active comparator: Standard Care

Participants will take GLP-1 RAs for 12 weeks as prescribed by regular treating provider

Interventions

Resistance Exercise

60 min/session, all for 2 sessions/week for 12 weeks

GLP-1 RAs

Participants will take GLP-1 RAs for 12 weeks

Primary outcome measure

  • Change in Body Composition [ Time Frame: From Baseline to Week 12 ]
  • Change in Quality of Life [ Time Frame: From Baseline to Week 12 ]

Central Contacts and Locations

Central contacts

Jiyeon Yoon, M.S.

512-817-4601jiy239@pitt.edu

Locations

Physical Activity Research Center, University of Pittsburgh

Recruiting

Pittsburgh, Pennsylvania, United States, 15219

Contacts

Jiyeon Yoon, M.S.

515-817-4601jiy239@pitt.edu

More Information

Sponsor

University of Pittsburgh

Last update posted

Jun 24, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Pittsburgh on 2026-06-24.